Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight

The major depressive disorder clinical trial analysis report delivers important insights into ongoing research of 75+ pipeline major depressive disorder drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

New York, USA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Major Depressive Disorder Clinical Trial Pipeline Boom as 75+ Companies are in the Race for Better Treatments | DelveInsight

The major depressive disorder clinical trial analysis report delivers important insights into ongoing research of 75+ pipeline major depressive disorder drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Major Depressive Disorder Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for major depressive disorder across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the major depressive disorder domain.

Major Depressive Disorder Clinical Trial Analysis Summary

• DelveInsight’s major depressive disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline major depressive disorder drugs. 
• Key major depressive disorder companies, such as Helus Pharma, Johnson & Johnson, Alto Neuroscience, Transneural Therapeutics, Synphatec, ACADIA Pharmaceuticals, GH Research, SIMR Biotech, Supernus Pharmaceuticals, Inc., Neurocrine Biosciences, Takeda, Xenon Pharmaceuticals Inc., Eli Lilly and Company, AbbVie Inc., Autobahn Therapeutics, and others, are evaluating new major depressive disorder drugs to improve the treatment landscape.
• Promising pipeline major depressive disorder therapies, such as HLP003, Seltorexant, ALTO-300, TN-001, SP-101, ACP-211, Mebufotenin, SPN-820, Osavampator, Azetukalner, ALTO-202, Brenipatide, Icalcaprant, Elunetirom, and others, are in different phases of major depressive disorder clinical trials.
• Approximately 12+ major depressive disorder drugs are in the late stages of development.
• Notable MoAs in major depressive disorder clinical trials include 5-HT2A receptor agonist, Orexin receptor type 2 antagonists, Melatonergic agonist and serotonergic antagonist, NMDA receptor antagonists, Serotonin (5-HT) agonist, Negative allosteric modulator of the GluN2B subunit of the NMDA receptor, Dual 5-HT2A partial agonist/5HT2B antagonist, ,GLP-1/GIP agonist, kappa opioid receptor (KOR) antagonist, CNS-TR agonist  and others.

Request a sample and discover the recent advances in major depressive disorder treatment @ https://www.delveinsight.com/report-store/major-depressive-disorder-pipeline-insight

What is Major Depressive Disorder?

Major Depressive Disorder (MDD), commonly known as depression, is a serious and prevalent mental health disorder characterized by persistent feelings of sadness, hopelessness, or loss of interest or pleasure in previously enjoyable activities. It can affect mood, thoughts, behavior, sleep, appetite, energy levels, concentration, and overall daily functioning. MDD can develop due to a combination of genetic, biological, psychological, and environmental factors and may vary in severity from mild to severe. Unlike temporary feelings of sadness, depressive symptoms typically persist for at least two weeks and can significantly interfere with an individual’s personal, social, and professional life. Treatment generally involves psychotherapy, antidepressant medications, or a combination of both, with treatment approaches tailored to the severity and needs of each patient.

Find out more about treatment for major depressive disorder @ Major Depressive Disorder New Treatment

A snapshot of the Pipeline Major Depressive Disorder Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
HLP003	Helus Pharma	III	5-HT2A receptor agonist	Oral
Seltorexant	Johnson & Johnson	III	Orexin receptor type 2 antagonists	Oral
ALTO-300	Alto Neuroscience	II	Melatonergic agonist and serotonergic antagonist	Oral
ACP-211	ACADIA Pharmaceuticals	II	NMDA receptor antagonists	Oral
Mebufotenin	GH Research	II	Serotonin (5-HT) agonist	Inhalation
ELE-101	AtaiBeckley	II	ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists	Intravenous
SP-101	Synphatec	I	NMDA receptor antagonists	Intravenous
TN 001	Transneural Therapeutics	Preclinical	Dual 5-HT2A partial agonist/ 5HT2B antagonist	Unspecified

Learn more about the major depressive disorder research @ Major Depressive Disorder Clinical Trials 

As per Stuti Mahajan, consulting manager at DelveInsight, the MDD treatment landscape is shifting toward rapid-acting and mechanistically differentiated therapies, with growing interest in psychedelics, neuroplasticity, glutamatergic signaling, orexin modulation, and precision psychiatry. HLP003 and seltorexant are among the most advanced candidates in Phase III, while ALTO-300, ALTO-202, and TN-001 expand the pipeline through circadian, NMDA, and non-hallucinogenic neuroplasticity mechanisms. Positive developments for DT120, VLS-01, BPL-003, and osavampator further support strong pipeline momentum. The future market outlook remains positive, driven by unmet needs in treatment-resistant depression, demand for faster and durable responses, and increasing treatment personalization, with the global MDD market projected to grow at a healthy rate over the coming years. However, regulatory requirements, safety, tolerability, reimbursement, and competition from established antidepressants will remain key factors influencing market adoption.

Recent Developments in Major Depressive Disorder Treatment Space

• In July 2026, Helus Pharma announced that it has completed enrollment in its APPROACH Phase III pivotal study of HLP003 in patients living with Major Depressive Disorder.
• In July 2026, AtaiBeckley Inc. announced that the last patient has been dosed in the Phase IIb Elumina trial evaluating VLS-01 for treatment-resistant depression (TRD). Topline data are expected by fourth quarter of 2026, and, subject to positive Phase II results and regulatory alignment, the company plans to advance VLS-01 into a Phase III program for major depressive disorder.
• In June 2026, Definium Therapeutics, Inc. announced positive topline results from Emerge, its first randomized, double-blind, placebo-controlled Phase III study evaluating a single dose of DT120 (lysergide) ODT 100 µg in adults with major depressive disorder (MDD).
• In May 2026, Transneural Therapeutics announced the presentation of new preclinical data for its lead candidate TN-001 at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting. The preclinical data showed that TN-001 rapidly promoted neuroplasticity and synaptogenesis, while demonstrating significant antidepressant-like effects in a depression model, supporting its potential as a rapid-acting, non-hallucinogenic therapy for major depressive disorder.
• In November 2025, Atai Beckley N.V. announced the successful completion of the strategic combination between atai Life Sciences and Beckley Psytech Limited in an all-share transaction. The combined company brings together world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address some of the most urgent unmet needs in mental health.
• In September 2025, Neurocrine Biosciences, Inc. announced the presentation of new data from the Phase II SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with once-daily oral administration of 1 mg osavampator (NBI-1065845). In recognition of the data presentation, Neurocrine was honored with the 2025 Poster Award at the 38th annual Psych Congress in San Diego.
• In September 2025, Johnson & Johnson announced results from the Phase III MDD3005 26-week clinical trial evaluating the efficacy and safety of seltorexant compared to quetiapine extended release (XR) as an adjunctive treatment in adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms. The findings were presented at this year’s annual U.S. Psychiatric and Mental Health Congress (Psych Congress), held from September 17-21 in San Diego, California.
• In July 2025, Atai Life Sciences and Beckley Psytech Limited jointly announced positive topline results from the eight-week, quadruple-masked, dose-finding, core stage of the Phase IIb clinical trial evaluating the efficacy and safety of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD). The study achieved its primary endpoint as well as all key secondary endpoints.
• In May 2025, Alto Neuroscience, Inc. announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting reinforcing safety and tolerability profile for ALTO-300 in major depressive disorder, in Scottsdale, Arizona, held May 27-30, 2025.
• In January 2025, Neurocrine Biosciences, Inc. announced the initiation of a Phase III registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly NBI-1065845), an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder (MDD). Positive topline data for the Phase II SAVITRI™ study of osavampator in adult subjects with MDD were announced in April 2024.

Scope of the Major Depressive Disorder Pipeline Report 

• Coverage: Global 
• Major Depressive Disorder Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Major Depressive Disorder Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Major Depressive Disorder Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Major Depressive Disorder Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Major Depressive Disorder Therapeutics Assessment By Mechanism of Action: 5-HT2A receptor agonist, Orexin receptor type 2 antagonists, Melatonergic agonist and serotonergic antagonist, NMDA receptor antagonists, Serotonin (5-HT) agonist, Negative allosteric modulator of the GluN2B subunit of the NMDA receptor, Dual 5-HT2A partial agonist/5HT2B antagonist, ,GLP-1/GIP agonist, kappa opioid receptor (KOR) antagonist, CNS-TR agonist  and others
• Key Major Depressive Disorder Companies: Helus Pharma, Janssen Research & Development, Alto Neuroscience, Transneural Therapeutics, Synphatec, ACADIA Pharmaceuticals, GH Research, SIMR Biotech, Supernus Pharmaceuticals, Inc., Neurocrine Biosciences, Takeda, Xenon Pharmaceuticals Inc., Eli Lilly and Company, AbbVie Inc., Autobahn Therapeutics, and others.
• Key Major Depressive Disorder Pipeline Therapies: HLP003, Seltorexant, ALTO-300, TN-001, SP-101, ACP-211, Mebufotenin, SPN-820, Osavampator, Azetukalner, ALTO-202, Brenipatide, Icalcaprant, Elunetirom, and others

Dive deep into rich insights for major depressive disorder cure, visit @ Major Depressive Disorder News

Table of Contents

1.	Major Depressive Disorder Pipeline Report Introduction
2.	Major Depressive Disorder Pipeline Report Executive Summary
3.	Major Depressive Disorder Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Major Depressive Disorder Clinical Trial Therapeutics
6.	Major Depressive Disorder Pipeline: Late-Stage Products (Pre-registration)
7.	Major Depressive Disorder Pipeline: Late-Stage Products (Phase III)
8.	Major Depressive Disorder Pipeline: Mid-Stage Products (Phase II)
9.	Major Depressive Disorder Pipeline: Early-Stage Products (Phase I)
10.	Major Depressive Disorder Pipeline Therapeutics Assessment
11.	Inactive Products in the Major Depressive Disorder Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Major Depressive Disorder Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the major depressive disorder clinical trials, reach out @ Major Depressive Disorder Medication

Related Reports

Major Depressive Disorder Market

Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MDD companies, including Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Luye Pharma, Relmada Therapeutics, BioLite Inc., VistaGen Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, Neurocrine Biosciences, Arrivo Bioventures, Sirstei Pharmaceuticals, Alto Neuroscience, Chase Therapeutics, Neumora Therapeutics, Inc., BlackThorn Therapeutics, Inc., Otsuka Pharmaceutical Co., Ltd., Fabre-Kramer Pharmaceuticals, Novartis, and others.

Generalized Anxiety Disorder Market

Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key generalized anxiety disorder companies including VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics INC., Bionomics Limited, Receptor Life Sciences, MannKind Corporation, and others.

Social Anxiety Disorder Market

Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key social anxiety disorder companies including Mochida Pharmaceutical, Lundbeck, Vistagen Therapeutics, Bionomics, EmpowerPharm, and others.

Alzheimer's Disease Market

Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics, and others.

Alzheimer's Disease Clinical Trial Analysis 

Alzheimer's Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alzheimer's Disease companies, including Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,  Otsuka Pharmaceutical Co., Ltd.,  Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd.,  Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679